The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)

Attention: There is an updated edition available for this report.
 
   Single User - $3,995
   Site License (one location, 10 users) - $5,995
   Corporate License - $7,990



Loading...
Published Aug 15, 2013 | 164 Pages | Pub ID: KLI5097517

The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)

Circulating tumor cells (CTCs) are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs and forming new tumors. These cells that leave the primary tumor are able to colonize distant organs in the body and initiate the process of metastasis; however, their biology is still not entirely elucidated.
Circulating tumor cells have tremendous utility in cancer research, aiding scientists in deciphering the complex biology of cancer metastasis. Besides the applications in cancer research, the detection and analysis of circulating tumor cells has enormous potential in the diagnosis and management of cancer, as current tools, such as tumor tissue biopsy or imaging technologies, have numerous limitations. This report, The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells, is Kalorama's detailed analysis of the potential opportunities for manufacturers of CTCs-based technologies. Analyst Adriana Rusu informs readers of the scientific basis of CTCs in an understandable fashion, and constructs models of revenue opportunity based on several dimensions - application area, cancer type and region - that can assist with business planning efforts.
Despite their potential, the detection and analysis of circulating tumor cells has been a challenging endeavor, and their significance in cancer not completely understood. Progress in the field of CTC-based cancer diagnostics and therapeutics has been thus far hampered by the rarity of these cells and the difficulty to isolate them from the patient’s blood. Nonetheless, in the past decade, numerous technological advances have contributed to a renewed interest in this field. The report considers these challenges and trends in the markets and provides data on the following:
  • Introduction and Overview of Biolgy Behind CTCs
  • Market and Forecast to 2017 For CTCs-based Technologies
  • Market Breakdown by Type of Cancer
  • Market Breakdown by Application Type (Research, Diagnostics)
  • Market Breakdown by Geographic Region
  • Current Isolation and Identification Methods
  • Uses in Prognosis, Diagnosis, Drug Development and Other Research
  • CTCs-based Products and Competitors
  • The Current State of Cancer Treatment, Incidence and Other Helpful Statistics
  • Collaboration and Partnerships
The global market for CTC detection, isolation and analysis devices is a heterogeneous and competitive market, constantly driven by technological innovation and demand for improved technologies. The market includes numerous competitors with different capabilities. These numerous specialized or research-based companies also develop and commercialize products for the detection, isolation and analysis of CTCs, and contribute considerably to the technological advancements in this field. As part of its extensive coverage, the report profiles several competitors in the market. The following companies are profiled:
  • AdnaGen AG
  • Advanced Cell Diagnostics, Inc.
  • ApoCell, Inc.
  • Aviva Biosciences Corporation
  • Biocept, Inc.
  • Biofluidica
  • BioView Ltd.
  • Celula, Inc.
  • Clearbridge Biomedics
  • Creatv MicroTech, Inc.
  • Cynvenio Biosystems
  • CytoTrack ApS
  • Epic Sciences
  • Fluidigm Corporation
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • Miltenyi Biotec GmbH
  • On-Q-ity
  • Parsortix/ANGLE
  • RareCells Diagnostics
  • ScreenCell
  • Silicon Biosystems
  • TeloVISION LLC
  • Veridex, LLC
  • Vitatex Inc.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times